Patents by Inventor Joseph T. Bruder
Joseph T. Bruder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170219560Abstract: The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.Type: ApplicationFiled: April 10, 2017Publication date: August 3, 2017Applicant: United States of America as Represented by the Secretary of the NavyInventors: Joseph T. Bruder, Imre Kovesdi, Duncan L. McVey, Douglas E. Brough, Richter C. King, Denise L. Doolan, Joao C. Aguair, Daniel J. Carucci, Martha Sedegah, Walter R. Weiss, Keith Limbach
-
Patent number: 9651543Abstract: The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.Type: GrantFiled: April 19, 2013Date of Patent: May 16, 2017Assignee: The United States of America as Represented by the Secretary of the NavyInventors: Joseph T. Bruder, Imre Kovesdi, Duncan L. McVey, Douglas E. Brough, C. Richter King, Denise Louise Doolan, Joao Carlos Aguair, Daniel John Carucci, Martha Sedegah, Walter R. Weiss, Keith Limbach
-
Publication number: 20170082607Abstract: The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.Type: ApplicationFiled: April 19, 2013Publication date: March 23, 2017Inventors: Joseph T. Bruder, Imre Kovesdi, Duncan L. McVey, Douglas E. Brough, C. Richter King, Denise Louise Doolan, Joao Carlos Aguair, Daniel John Carucci, Martha Sedegah, Walter R. Weiss, Keith Limbach
-
Patent number: 9254316Abstract: The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum circumsporozoite protein (CSP) operably linked to a human CMV promoter, and/or (b) a second adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum apical membrane antigen 1 (AMA-1) antigen operably linked to a human CMV promoter.Type: GrantFiled: May 9, 2013Date of Patent: February 9, 2016Assignee: The United States of America as represented by the Secretary of the NavyInventors: Joseph T. Bruder, C. Richter King, Thomas Richie, Keith Limbach, Denise Louise Doolan
-
Publication number: 20150157700Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising a nucleic acid sequence encoding one or more Plasmodium antigens and one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein, as well as a method of inducing an immune response against Plasmodium falciparum in a mammal by administering the adenovirus or adenoviral vector to the mammal.Type: ApplicationFiled: February 1, 2013Publication date: June 11, 2015Inventors: Joseph T. Bruder, Jason G.D. Gall, Duncan McVey, Douglas E. Brough
-
Patent number: 8920813Abstract: The invention relates to a replication-deficient adenoviral vector comprising two or more nucleic acid sequences encoding Dengue virus antigens and a chimeric hexon protein. The chimeric hexon protein comprises a first portion and a second portion. The first portion comprises at least 10 contiguous amino acid residues from a first adenovirus serotype (e.g., serotype 5 adenovirus hexon protein), optionally with one amino acid substitution. The second portion comprises (a) at least one hypervariable region (HVR) of a hexon protein of an adenovirus of a second adenovirus serotype, or (b) at least one synthetic hypervariable region (HVR) that is not present in the hexon protein of the wild-type adenovirus of the first adenovirus serotype.Type: GrantFiled: December 20, 2011Date of Patent: December 30, 2014Assignee: GenVec, Inc.Inventors: Joseph T. Bruder, Duncan McVey, Douglas E. Brough
-
Publication number: 20140335128Abstract: The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum circumsporozoite protein (CSP) operably linked to a human CMV promoter, and/or (b) a second adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum apical membrane antigen 1 (AMA-1) antigen operably linked to a human CMV promoter.Type: ApplicationFiled: May 9, 2013Publication date: November 13, 2014Inventors: Joseph T. Bruder, C. Richter King, Thomas Richie, Keith Limbach, Denise Louise Doolan
-
Publication number: 20140314809Abstract: The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.Type: ApplicationFiled: April 19, 2013Publication date: October 23, 2014Inventors: Joseph T. Bruder, Imre Kovesdi, Duncan L. McVey, Douglas E. Brough, C. Richter King, Denise Louise Doolan, Joao Carlos Aguair, Daniel John Carucci, Martha Sedegah, Walter R. Weiss, Keith Limbach
-
Patent number: 8765146Abstract: The invention provides adenoviral vectors comprising an adenoviral genome comprising heterologous antigen-encoding nucleic acid sequences, such as Plasmodium nucleic acid sequences, operably linked to promoters. The invention further provides a method of inducing an immune response against malaria in a mammal comprising administering the adenoviral vectors to the mammal.Type: GrantFiled: August 31, 2006Date of Patent: July 1, 2014Assignees: GenVec, Inc., The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The United States of America, as represented by the Secretary of the NavyInventors: Joseph T. Bruder, Imre Kovesdi, C. Richter King, Duncan L. McVey, Damodar R. Ettyreddy, Denise Louise Doolan, Daniel John Carucci
-
Publication number: 20130337008Abstract: The invention relates to a replication-deficient adenoviral vector comprising two or more nucleic acid sequences encoding Dengue virus antigens and a chimeric hexon protein. The chimeric hexon protein comprises a first portion and a second portion. The first portion comprises at least 10 contiguous amino acid residues from a first adenovirus serotype (e.g., serotype 5 adenovirus hexon protein), optionally with one amino acid substitution. The second portion comprises (a) at least one hypervariable region (HVR) of a hexon protein of an adenovirus of a second adenovirus serotype, or (b) at least one synthetic hypervariable region (HVR) that is not present in the hexon protein of the wild-type adenovirus of the first adenovirus serotype.Type: ApplicationFiled: December 20, 2011Publication date: December 19, 2013Applicant: GENVEC, INC.Inventors: Joseph T. Bruder, Duncan McVey, Douglas E. Brough
-
Patent number: 8450055Abstract: The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.Type: GrantFiled: August 25, 2006Date of Patent: May 28, 2013Assignee: The United States of America as Represented by the Secretary of the NavyInventors: Joseph T. Bruder, Imre Kovesdi, Duncan L. McVey, Douglas E. Brough, C. Richter King, Denise Louise Doolan, Joao Carlos Aguair, Daniel John Carucci, Martha Sedegah, Walter R. Weiss, Keith Limbach
-
Patent number: 8323663Abstract: The invention is directed to an adenoviral vector comprising at least one nucleic acid sequence encoding an aphthovirus antigen and/or a cytokine operably linked to a promoter. The adenoviral vector is replication-deficient and requires at most complementation of both the E1 region and the E4 region of the adenoviral genome for propagation. The invention also is directed to a method of inducing an immune response in a mammal comprising administering to the mammal a composition comprising the aforementioned adenoviral vector.Type: GrantFiled: May 8, 2008Date of Patent: December 4, 2012Assignee: GenVec, Inc.Inventors: Douglas E. Brough, Joseph T. Bruder, C. Richter King, Marvin J. Grubman, John G. Neilan
-
Publication number: 20100278870Abstract: The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum circumsporozoite protein (CSP) operably linked to a human CMV promoter, and/or (b) a second adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum apical membrane antigen 1 (AMA-1) antigen operably linked to a human CMV promoter.Type: ApplicationFiled: January 9, 2008Publication date: November 4, 2010Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Joseph T. Bruder, C. Richter King, Thomas Richie, Keith Limbach, Denise Louise Doolan
-
Publication number: 20100222234Abstract: The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.Type: ApplicationFiled: August 25, 2006Publication date: September 2, 2010Inventors: Joseph T. Bruder, Imre Kovesdi, Duncan L. McVey, Douglas E. Brough, C. Richter King, Denise Louise Doolan, Joao Carlos Aguair, Daniel John Carucci, Martha Sedegah, Walter R. Weiss, Keith Limbach
-
Publication number: 20090264509Abstract: The invention is directed to an adenoviral vector comprising at least one nucleic acid sequence encoding an aphthovirus antigen and/or a cytokine operably linked to a promoter. The adenoviral vector is replication-deficient and requires at most complementation of both the E1 region and the E4 region of the adenoviral genome for propagation. The invention also is directed to a method of inducing an immune response in a mammal comprising administering to the mammal a composition comprising the aforementioned adenoviral vector.Type: ApplicationFiled: May 8, 2008Publication date: October 22, 2009Applicant: GENVEC, INC.Inventors: Douglas E. Brough, Joseph T. Bruder, C. Richter King
-
Publication number: 20090148477Abstract: The invention provides adenoviral vectors comprising an adenoviral genome comprising heterologous antigen-encoding nucleic acid sequences, such as Plasmodium nucleic acid sequences, operably linked to promoters. The invention further provides a method of inducing an immune response against malaria in a mammal comprising administering the adenoviral vectors to the mammal.Type: ApplicationFiled: August 31, 2006Publication date: June 11, 2009Applicant: GENVEC, INC.Inventors: Joseph T. Bruder, Imre Kovesdi, C. Richter King, Duncan L. McVey, Damodar R. Ettyreddy, Denise Louis Doolan, Daniel John Carucci, Keith Limbach
-
Publication number: 20080248060Abstract: The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum circumsporozoite protein (CSP) operably linked to a human CMV promoter, and/or (b) a second adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum apical membrane antigen 1 (AMA-1) antigen operably linked to a human CMV promoter.Type: ApplicationFiled: January 9, 2008Publication date: October 9, 2008Applicants: GENVEC, INC., THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARInventors: Joseph T. Bruder, C. Richter King, Thomas Richie, Keith Limbach, Denise Louis Doolan
-
Patent number: 7195896Abstract: The present invention provides multiply deficient adenoviral vectors and complementing cell lines. Also provided are recombinants of the multiply deficient adenoviral vectors and a therapeutic method, particularly relating to gene therapy, vaccination, and the like, involving the use of such recombinants.Type: GrantFiled: September 26, 2001Date of Patent: March 27, 2007Assignee: GenVec, Inc.Inventors: Imre Kovesdi, Douglas E Brough, Duncan L McVey, Joseph T Bruder, Alena Lizonova
-
Patent number: 6998263Abstract: The present invention provides a library of viral vectors, wherein each member comprises a first heterologous DNA encoding a first gene product and a second heterologous DNA encoding a second gene product. The first heterologous DNA is common to each member of the library, while the second heterologous DNA varies between members of the library. The present invention additionally provides a method of constructing a library of viral vectors. The method comprises carrying out homologous recombination between a first DNA molecule and a second DNA molecule to form a pool of intermediate viral vector genomes. One or more linear third DNA molecules are ligated into the pool of intermediate viral genomes to produce a library of viral vector genomes. Alternatively, homologous recombination between linear DNA molecules and recipient DNA molecules produces a library of viral vector genomes. The library of viral vector genomes is converted into a library of viral vectors.Type: GrantFiled: February 9, 2001Date of Patent: February 14, 2006Assignee: GenVec, Inc.Inventors: Imre Kovesdi, Duncan L. McVey, Thomas J. Wickham, Joseph T. Bruder, Douglas E. Brough
-
Patent number: 6756044Abstract: The present invention provides a complex that includes a virion having a ligand that recognizes an epitope present on an immune effector cell surface and at least a first nucleic acid encoding a first non-native antigen. The invention also provides a library including a plurality of such complexes, in which antigens of at least two of the plurality are different. Using such reagents, the invention provides a method of precipitating an immune response within an immune effector cell, wherein such a complex is delivered to the cell under conditions sufficient for the cell to mount an immune response to the antigen. When applied in vivo, the method can serve to immunize an animal from the pathogen. Moreover, using a library including a plurality of complexes, which contains at least one test antigen, the invention provides a method of assessing the antigenicity of the test antigen.Type: GrantFiled: July 17, 2000Date of Patent: June 29, 2004Assignee: GenVec, Inc.Inventors: Petrus W. Roelvink, Joseph T. Bruder, Imre Kovesdi, Thomas J. Wickham